Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Highlights,Financial firms have revised their evaluations of Regeneron Pharmaceuticals.,The company reported strong earnings ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...